Kornimate/medical-research-clean huggingface dataset:
the effects of intratesticular prp injection in men with azoospermia or cryptozoospermia

Conditions: Azoospermia, Nonobstructive

Summary: the study will be conducted in men with a diagnosis of non-obstructive azoospermia or cryptozoospermia after obtaining written informed consent. the diagnosis of azoospermia and cryptozoospermia will be based on two semen analyses performed at least 15 days apart, followed by a documented micro testicular sperm extraction (tese). a detailed history will be obtained, physical examination and laboratory evaluation will be performed prior to treatment. in physical examination, testicular volumes will be evaluated using an orchiometer. serum fsh and testosterone values will be determined. prp will be prepared by centrifugation of approximately 20 ml autologous blood obtained by phlebotomy. prp (3 ml) will be administered into the seminiferous tubule or interstitial space of each testis. sperm analysis, testicular volume (using orchiometer), serum fsh and testosterone levels will be reevaluated at 8 weeks post-procedure. micro tese will performed on the third month after prp procedure.

platelet-rich plasma (prp) is a unique autologous agent derived from blood that is rich in growth factors, cytokines, and hormones; it has been reported to reduce oxidative stress and reactive oxygen species generation and upregulate the expression of various antioxidant enzymes. prp is used in a variety of clinical applications in cell therapy. based on world health organization guidelines, azoospermia is diagnosed when the absence of sperm is observed in two semen samples. based on world health organization (who), cryptozoospermia is diagnosed when spermatozoa cannot be observed in a fresh semen sample; however, it is found after an extended centrifugation and microscopic search. all patients require a clinical work-up with physical examination, endocrine evaluation (follicle stimulating hormone (fsh), luteinizing hormone (lh) and testosterone) and genetic analysis. scrotal and transrectal ultrasounds will be performed as indicated. platelet-rich plasma (prp), with its rich growth factor composition, has proven beneficial in regenerative therapy. the potential therapeutic role of prp has not been studied in testis for non-obstructive azoospermia and cryptozoospermia. the investigators will investigate sperm parameters in non-obstructive azoospermic and crypotozoospermic patients treated with prp.

Eligibility criteria:
inclusion criteria: * azoospermia in at least 2 prior semen analysis. * diagnosis of non-obstructive azoospermia or diagnosis of cryptozoospermia exclusion criteria: * obstructive azospermia * anatomical abnormalities in the genital tract, * cancer, * hepatitis * patients with systemic medical problems * patients with chromosomal disorders
finnish cardioversion study ii

Conditions: Atrial Fibrillation

Summary: this is a retrospective multi-center patient cohort study investigating patients with persistent atrial fibrillation (af) and elective cardioversion (ecv). the aim is to identify clinical predictors for ineffective ecv to improve management quality of persistent af.

data was gathered from patient registries of two finnish university hospitals and two regional hospitals in a time period of 2003-2015. a data search was conducted using the icd-10 code for atrial fibrillation and ncsp code for cardioversion. all patients with af and performed cardioversion were eligible for the study. initially, 2373 patients were captured after which all ecv cases were identified and included manually in the study using a structured electronic case report form. the study cohort comprised 1998 ecvs and 1342 patients. follow-up data was gathered for 30 days after ecv and all strokes, transient ischemic attacks, arrhythmic complications, af recurrences and failed cardioversions were recorded and subjected to careful exploration. ibm spss statistics software version 22.0 was used to perform all analyses.

Eligibility criteria:
inclusion criteria: * all patients with persistent (\>48h) atrial fibrillation and elective electrical cardioversion exclusion criteria: * cardioversions for patients with acute (\<48h) atrial fibrillation * pharmacological cardioversions

Keywords: atrial fibrillation cardioversion
the south-east asian transgender health cohort

Conditions: HIV; STIs; HCV

Summary: this is a prospective observational cohort study that will enroll 300 hiv-negative transgender people and 150 transgender people living with hiv from 4 community health centers in thailand, vietnam, and the philippines. each participant will be followed-up until the completion of 24 months.

this prospective observational cohort study will longitudinally track physical (e.g. hiv/sti, sexual risk behavior, gender affirmation, clinical information, cardiovascular health, medical history) and mental health (e.g. stigma and discrimination, gender-based violence, anxiety, depression); identify biomedical, structural, and psychosocial factors impacting physical and mental health among transgender people; describe the structural barriers to healthcare experienced by transgender people as well as develop the guidance on holistic healthcare policies for transgender people.

Eligibility criteria:
inclusion criteria: * thai/vietnamese/filipino nationality * aged ≥ 18 years old * self-identify as a transgender woman or transgender man * have signed consent form exclusion criteria: * none

Keywords: hiv
a clinical trial of thread-embedding therapy at acupuncture point for simple obesity

Conditions: Weight Loss; Simple Obesity

Summary: thread-embedding therapy has been used for treating obesity in recent years. this research is aimed to observe the clinical effect of thread-embedding therapy in treating simple obesity. one hundred patients is planned to be enrolled in the research and receive a thread-embedding therapy. the level of bmi, serum triglyceride, cholesterol and fasting blood glucose will be adopted for evaluation before and after therapy.

each participant will receive thread-embedding therapy every two weeks, and eight times in all.blood test will be taken at the beginning of the first week of the whole therapy, and at the end of the 8th therapy. during the periods of whole therapy, the participants shall follow diets control and physical exercise as the protocol described.

Eligibility criteria:
inclusion criteria: * patients with age from 18 to 60 years old; * patients with bmi≥ 24, meanwhile waist more than 85 cm (for male) or 80 cm (for female); * patients with diagnosed as central adiposity and/or simple obesity according to the diagnosis criteria； * patients who is willing to cooperate with the test treatment and signed informed consent. exclusion criteria: * pregnant or lactating women; * patients who syncope after acupuncture； * patients who present hypersensitivity reactions after acupoint-embedding therapy; * patients with serious heart, liver, kidney, brain and other diseases; * patients with severe primary diseases; * patients with psychiatric diseases； * patients who did not meet the criteria for the inclusion criteria while investigators find out during the trial; * participants who did not complete dietary control and physical exercise as the protocol described.

Keywords: simple obesity thread-embedding therapy acupuncture
hydra registry - uk

Conditions: Aortic Valve Stenosis

Summary: the study will evaluate the efficacy and safety of transcatheter aortic valve implantation (tavi) using the hydra transcatheter aortic heart valve (thv) series, in patients with severe aortic stenosis up to 1-year after the procedure. this will include an evaluation of the preservation of coronary access post implant by attempting to selectively engage both the right and left coronary arteries through standardised angiographic views. the study will also examine the utility of 72 hours of post discharge remote ambulatory continuous electrocardiogram (ecg) monitoring using the novel checkpoint cardio system where it is clinically appropriate.

this is a prospective, observational, multi-centre study. the aim of this study is to collect clinical, procedural, and follow-up data in order to evaluate the efficacy and safety of the hydra thv series (vascular innovations co. ltd., nonthaburi, thailand). additionally, the study will conduct the following evaluation: 1. the remote ambulatory cardiac monitoring (racm) using the checkpoint cardio system, consisting of 72 hours of continuous electrocardiogram (ecg) monitoring, will be evaluated post hospital discharge where it is clinically appropriate. 2. coronary access will be evaluated immediately post-tavi by attempting to selectively engage both the right and left coronary arteries through standardised angiographic views. this will be done in a sub-set of patients who are either known to have coronary artery disease, did not have coronary angiogram prior to tavi or where it is felt to be clinically appropriate for other reasons post implant. following discharge, clinical follow-ups are scheduled at 45 days (±14 days), and 1-year (±30 days).

Eligibility criteria:
inclusion criteria: 1. patients with severe aortic stenosis eligible for transfemoral tavi procedure as per local heart team evaluation 2. full understanding and willing to provide informed consent to study enrolment 3. age ≥ 18 years exclusion criteria: 1. contraindications to tavi (e.g., anatomically phenotypes, intracardiac mass, thrombus, vegetation, endocarditis) 2. refusal to provide informed consent to study enrolment 3. patients with severe aorta or peripheral artery disease precluding transfemoral approach of tavi 4. patients with significant calcification of the aortic annulus and in the left ventricular outflow tract (lvot), or/and excess calcium within each cusp, or those who are deemed unsuitable for the hydra thv series based on the clinical judgment of the investigator.

Keywords: aortic valve stenosis, tavi, hydra
relaxin, matrix metalloproteinase-2 and interleukin-6 in women with chronic pelvic pain

Conditions: Endometriosis

Summary: in our study, by evaluating the serum and vaginal-peritoneal fluid levels of relaxin, matrix metalloproteinase-2 and interleukin-6 in women over 35 years of age with chronic pelvic pain, the investigators aimed to reveal their potential to be an important marker in the diagnosis of deep infiltrative endometriosis, thus enabling early diagnosis with lower cost and results that can be obtained in a short time.the investigators aim to reveal its relationship with follow-up. in our study, the values of relaxin, mmp-2 or il-6 from vaginal fluids were found to be significantly higher than the control group in the prediction and follow-up of deep infiltrative endometriosis. this supports the role of relaxin and mmp-2 as well as il-6 in the pathophysiology of deep infiltrative endometriosis. histologically based and multicenter randomized controlled studies with more patients are needed to elucidate the etiology and pathophysiology of endometriosis.

10 cc of vaginal washing fluid, serum samples on the day of operation and 20 cc of pelvic washing fluid during laparoscopy were taken from all patients before the operation. patients were included in the fa group according to the enzian classification. patients' age, bmi, gravida, parity, obstetric history such as pregnancy, ethnic origin, educational status, preoperative and postoperative evaluation for chronic pelvic pain, laboratory tests (routine tests such as ca125, crp, fsh, lh, e2, p), preoperative and postoperative hormonal values were recorded. relaxin, mmp-2 and il-6 values from vaginal washing fluid, peritoneal washing fluid and serum samples of the patients in the control and study groups were compared.

Eligibility criteria:
inclusion criteria: endometriosis patients adenomyosis patients exclusion criteria: ovarian endometriosis chronic pelvic pain with another reason

Keywords: chronic pelvic pain deep infiltrative endometriosis relaxin il-6 mmp-2
filgrastim for the promotion of collateral growth in patients with cad

Conditions: Coronary Artery Disease

Summary: the purpose of this study in humans with stable coronary artery disease (cad) treatable by pci (percutaneous coronary intervention) is to evaluate the safety and efficacy of subcutaneous delivery of recombinant granulocyte colony stimulating factor rg-csf (filgrastim, neupogen®, amgen switzerland) with regard to the promotion of collateral growth.

the purpose of this study in humans with stable coronary artery disease (cad) treatable by pci (percutaneous coronary intervention) is to evaluate the safety and efficacy of subcutaneous delivery of recombinant granulocyte colony stimulating factor rg-csf (filgrastim, neupogen®, amgen switzerland) with regard to the promotion of collateral growth.

Eligibility criteria:
inclusion criteria: * age \> 18 years old * 1- to 3-vessel coronary artery disease (cad) * stable angina pectoris * at least 1 stenotic lesion suitable for pci * no q-wave myocardial infarction in the area undergoing cfi measurement * written informed consent to participate in the study exclusion criteria: * patients admitted as emergencies * acute myocardial infarction * unstable cad * cad treated best by cabg * patients with overt neoplastic disease * patients with diabetic retinopathy * liver or kidney disease * pre-menopausal women

Keywords: cad g-csf collaterals cfi perfusion
an observational study investigating the positioning of epidural catheters and their function during labour analgesia

Conditions: Labour Analgesia, Epidural Anaesthesia

Summary: this is a small observational study investigating the physical changes that occur to epidural catheters after insertion for obstetric anaesthesia. using the observed physical changes as a correlate for the position of the catheter in the patient we will investigate a connection between the position and e function during labour. this information may be useful in guiding the physicians responses to epidurals that do not provide adequate analgesia to aid in deciding on the most appropriate action


Eligibility criteria:
inclusion criteria: * any women in labour requesting epidural anaesthesia exclusion criteria: * none
the effect of facial plane blocks on postoperative recovery quality in hip surgery

Conditions: Hip Fracture

Summary: the aim of this study was to evaluate the effect of ultrasound-guided pericapsular nerve block, fascia iliaca compartment block, and femoral block on the quality of recovery as part of multimodal analgesia before hip surgery under spinal anesthesia.

orthopedic procedures have become increasingly common in clinical practice. with the increasing elderly population, there have been significant developments in recent years in the field of perioperative pain management and anesthesia strategies for patients scheduled for hip surgery. patients undergoing hip surgery may experience severe pain both postoperatively and during the positioning of the patient during surgery. this leads to increased sympathetic activation such as tachycardia and hypertension in patients, especially in the elderly population, and some undesirable complications due to the patients' existing comorbidities. therefore, pain management strategies for patients undergoing hip surgery are based on a range of anesthesia techniques, including the use of opioids, neuraxial anesthesia (spinal, epidural, or a combination of them), nerve blocks, especially pericapsular nerve block (peng), fascia iliaca compartment block (ficb) and femoral block). reducing patients' pain and improving the quality of postoperative recovery has become increasingly important. the quality of recovery-15 (qor-15) is a 15-question questionnaire validated to assess postoperative recovery. this questionnaire assesses patients' pain, physical comfort, physical independence, psychological support, and emotional status in the early postoperative period. the aim of this study was to evaluate the effect of ultrasound-guided peng block, ficb block, and femoral block on the quality of recovery as part of multimodal analgesia before hip surgery under spinal anesthesia.

Eligibility criteria:
inclusion criteria: * elective hip fracture, * 18-85 years * american society of anaesthesiology (asa) i-iii exclusion criteria: * patients planned for general anesthesia * with multiple fractures * bleeding disorder * peripheral neuropathy * mental disorder * local anesthetic allergy * contraindications for spinal anesthesia (local infection, etc.) * declining to give written informed consent

Keywords: regional anesthesia postoperative pain recovery quality hip fracture
molecular investigation of non alcoholic fatty liver diseases in obese patients

Conditions: Liver Disease

Summary: non alcoholic fatty liver diseases (nafld) are represented by two main pathological conditions, hepatic steatosis (hs) and non alcoholic steatohepatitis (nash), which are characterized by the accumulation of fat in the liver. the diagnosis of these two entities is achieved by histology and neither imaging nor biochemical markers are accurate enough to discriminate them. at the contrary of hs, nash features hepatocyte necrosis, inflammation and fibrosis of variable intensity that could progress and ultimately evolve to cirrhosis. therefore, it is important to distinguish between hs and nash in order to treat the patients accordingly. in this study, the investigators aim to understand the molecular mechanisms that govern the transition from benign steatosis to complicated nash. the investigators will analyze by "q-rt-pcr" and "dna microarray" technologies in the liver of obese patients, the expression of genes that are susceptible to be involved in the pathogenesis of nafld and identify the potential signaling pathways responsible for the progression of the disease.


Eligibility criteria:
inclusion criteria: * group t(n=30): patient without central adiposity, without insulin resistance, operated for cholecystectomy or a benign liver tumor * group a (n=30): patient with central adiposity, insulin resistance and hepatic steatosis (histology). * group b (n=30): patient with central adiposity, insulin resistance and steatohepatitis ± hepatic fibrosis (histology). exclusion criteria: * viral or autoimmune hepatitis * hematochromatosis * alcohol consumption (\> 20 g/24h women, \>30 g/24h men) * type 1 diabetes * inflammation or infection before procedure * abnormal hemostasis or coagulation- pregnancy

Keywords: metabolic syndrome- hepatic steatosis- steatohepatitis - gene expression non alcoholic fatty liver disease (nfald)
lifestyle interventions for overweight adults with mental illness

Conditions: Mental Health Disorder

Summary: the purpose of this study is to examine the lifestyle intervention on life quality and mental health among overweight adults with severe mental illness in shenzhen, china. a total of 210 overweight adults with severe mental illness will be randomly allocated to intervention group and control group. participants in the intervention groups will receive a 10-month lifestyle intervention while the control group will be waitlisted. a group of investigators will measure the anthropocentric indicators, blood pressure, lifestyle, life quality, and mental health for all participants.

previous studies suggest that overweight is an important risk factor for life quality and mental health among patients with severe mental illness. findings on chinese adults regarding this issue are limited. thus, we aim to assess the lifestyle intervention on life quality and mental health among overweight adults with severe mental illness in shenzhen, china. a total of 210 overweight adults with severe mental illness will be randomly allocated to two groups. participants in the intervention groups will receive a 10-month lifestyle intervention while the control group will be waitlisted. in the intervention group, participants will receive lifestyle education delivered by trained staffs from wuhan university. the main objective of the lifestyle education is to raise participants' awareness regarding the health complications related to obesity and subsequently to promote weight loss through behavioural modifications. participants will be advised to reduce energy intake by having three main meals and avoiding snacks; limiting intake of sugary food and beverages as well as fried and fatty foods; increasing intake of fruits and vegetables, etc. they will be asked to increase physical activity, aiming for a minimum 150 min of moderate-intensity exercise per week and/or 10,000 steps per day. outcome measurement include height, weight, blood pressure, dietary habits, sleep, physical activity, life quality, and mental health that will be measured by a group of trained investigator for all participants.

Eligibility criteria:
inclusion criteria: * 18-65 years * with severe mental illness * bmi\>=24.0 * live in this district for 1 year at least. exclusion criteria: * disability * refuse to participate * pregnant woman * severe chronic diseases, such as cancer.
assessing the impact of a plant-based diet for diabetes prevention

Conditions: Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)

Summary: the primary purpose of this study is to determine the sex-specific metabolic and molecular response, among adults with prediabetes, when moving from a western diet to plant-based diet.

plant-based diets that are abundant in myoinsitol and d-chiro inositol (mi and dci) increase insulin sensitivity by promotion of insulin signaling lowering serum insulin and improving insulin resistance. the western diet contributes to chronic metabolic inflammation often leading to the development of metabolic diseases. there is known metabolic improvement among men compared to women when following a plant-based diet or intensive lifestyle modifications. through this study we look to identify the pathways in which plant-based diet impact skeletal muscle inositol metabolites among sexes (men vs. women) and improve insulin sensitivity.

Eligibility criteria:
inclusion criteria: * body mass index greater than or equal to 27 * high waist circumference (women greater than or equal to 35"; men greater than or equal to 40") * prediabetes (based on fasting glucose 100-125 mg/dl, hba1c 5.7-6.4, or 2-hr post-oral glucose tolerance test glucose screen between 140-199mg/dl) * physical activity below national guidelines * aged 30-55 (premenopausal for women) * following a western diet exclusion criteria: * diabetes diagnosis * take medications that may affect insulin sensitivity * more than 5% weight change within 6 months of screening * history of bariatric surgery * report any dietary supplement, medication, or medical condition known to significantly affect weight or metabolism * take hormone replacement therapy * consume 3 or more servings of combined fruit and vegetables daily and/or 3 or more servings of whole grains daily * any food allergy more severe than grade 1 on the cofar grading scale for systemic allergic reactions, version 3.0 or allergy to lidocaine